STOCK TITAN

Glucotrack Stock Price, News & Analysis

GCTK Nasdaq

Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.

Glucotrack (GCTK) delivers innovative diabetes management solutions through non-invasive and implantable glucose monitoring technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and market developments.

Access real-time information about regulatory milestones, product certifications, and strategic partnerships. Our curated feed includes earnings reports, clinical trial outcomes, and technology updates directly impacting GCTK's position in the medical device sector.

Key coverage areas include FDA/EU regulatory progress, implantable CBGM system trials, and commercial expansion initiatives. Bookmark this page for streamlined tracking of Glucotrack's progress in revolutionizing blood glucose measurement through cutting-edge ultrasound and electromagnetic technologies.

Rhea-AI Summary

Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on diabetes management, has announced the appointment of Sandie Martha as Vice President of Clinical Operations. With over 20 years of experience in clinical research, Martha brings expertise in leading global clinical trials for glucose monitoring and cardiology. Her role will be important in executing Glucotrack's Clinical Trial Program for their Continuous Blood Glucose Monitor (CBGM).

Martha's extensive background includes leadership positions at Glysens, Dexcom, and Truvian, where she managed various aspects of clinical trials and regulatory submissions. Her appointment is seen as a strategic move to advance Glucotrack's CBGM technology through clinical trials and ultimately bring it to market for millions of people living with diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
-
Rhea-AI Summary

Glucotrack Inc. (Nasdaq: GCTK) presented new findings at the ADCES 2024 Annual Conference, revealing strong interest in their innovative Continuous Blood Glucose Monitor (CBGM) concept. The market research study showed that over 50% of surveyed diabetes patients are open to adopting this new technology.

Key features attracting interest include:

  • Long-term sensor life (up to 3 years)
  • No wearable component
  • Real-time blood glucose readings

The study included 757 respondents with intensive insulin therapy, comprising current CGM users (67%), non-users (25%), and ex-users (8%). Glucotrack's CBGM concept aims to address unmet needs in diabetes management, offering a more convenient and less intrusive monitoring solution. The company has made significant clinical progress, completing successful preclinical studies and planning to initiate human clinical trials later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.74%
Tags
none
-
Rhea-AI Summary

Glucotrack Inc. (Nasdaq: GCTK) announced a poster presentation at the Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference in New Orleans, LA, from August 9-12, 2024. The poster, titled 'Evaluating Acceptance of a Continuous Blood Glucose Monitor for Insulin-Requiring People with Diabetes', will showcase market research data on the acceptance of Glucotrack's Continuous Blood Glucose Monitor (CBGM) concept among people with type 1 and type 2 diabetes.

CEO Paul V. Goode emphasized the growing interest in expanding glucose monitoring options. The poster session is scheduled for Saturday, August 10, from 12:15 PM to 1:15 PM Eastern time. Glucotrack will make the poster available on their website following the conference presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.4%
Tags
none
Rhea-AI Summary

Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focusing on diabetes management, has secured $4 million in funding from its leading shareholder, John Ballantyne. This funding will support the upcoming First in Human clinical trial for their innovative Continuous Blood Glucose Monitor (CBGM) technology.

CEO Paul V. Goode, PhD, highlighted the company's significant progress in developing their CBGM technology, describing it as a less burdensome approach to glucose monitoring. Ballantyne expressed confidence in the company's potential to deliver strong clinical value to the diabetes community and meaningful value to shareholders, citing the technology's potential to be disruptive in the large and growing diabetes market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
-
Rhea-AI Summary

Glucotrack has appointed Andy Balo to its Board of Directors, effective immediately. Balo, a veteran in the diabetes industry, brings decades of experience in regulatory, clinical, and quality domains. He played a key role in shaping Dexcom over 22 years and has coordinated numerous glucose monitoring regulatory submissions and clinical trials globally. Balo has also held leadership roles at St. Jude Medical, Baxter, Pacesetter, and Endocardial Solutions, and has served on several FDA panels. His expertise will be invaluable as Glucotrack advances its continuous blood glucose monitoring technology through clinical and regulatory milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
management
-
Rhea-AI Summary

Glucotrack (Nasdaq: GCTK) has announced the successful completion of a 60-day preclinical study for its innovative epidural continuous glucose monitoring sensor. The sensor, implanted in the epidural space of animals, closely tracked glucose levels comparable to both commercially available blood glucose monitors and subcutaneous CGMs. No abnormal clinical signs or delayed latent effects were observed during the study, supporting the sensor's safety and efficacy. This advancement holds promise for simplifying disease management in patients with painful diabetic neuropathy (PDN), a condition affecting over 7 million Americans. CEO Paul V. Goode expressed confidence in the sensor's performance and its potential benefits for diabetes patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
Rhea-AI Summary

Glucotrack (Nasdaq: GCTK), a medical technology company specializing in diabetes management, announced its participation in the Sidoti Small Cap Investor Conference. CEO Paul V. Goode will present on June 12, 2024, at 3:15 PM ET, and will also engage in one-on-one meetings. Interested parties can register for the webcast through a provided link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.3%
Tags
conferences
-
Rhea-AI Summary

Glucotrack announced the successful completion of a 90-day preclinical study for its Continuous Blood Glucose Monitor (CBGM), demonstrating sustained accuracy with a Mean Absolute Relative Difference (MARD) of 4.7%. The study, which involved a larger number of animal subjects than previous studies, showcased the CBGM's ability to offer real-time blood glucose measurement without the lag associated with subcutaneous sensors. The device showed no significant adverse effects and outperformed both a commercial blood glucose monitor and a subcutaneous glucose monitor. Glucotrack plans to initiate human clinical trials later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
-
Rhea-AI Summary

Glucotrack announced promising results from a 30-day segment of its 60-day long-term preclinical study on an epidural glucose monitoring sensor. The sensor, implanted in the epidural space, successfully tracked blood glucose levels and matched the performance of a commercial subcutaneous CGM. No complications or abnormal clinical signs were observed, showcasing the safety and potential efficacy of the device for managing painful diabetic neuropathy. The ongoing study aims to further validate the sensor's long-term performance and durability, potentially benefiting millions of diabetics if approved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
News
Rhea-AI Summary

Glucotrack announced a 1-for-5 reverse stock split effective May 20, 2024. Post-split, the shares will continue to trade under the symbol 'GCTK' on Nasdaq, with a new CUSIP number 45824Q606. This move reduces the outstanding shares from 27,392,996 to approximately 5,478,599 and the authorized shares from 500,000,000 to 100,000,000. Fractional shares will not be issued; instead, cash will be paid for fractions based on the average closing price before the split. This reverse split aims to meet Nasdaq's $1.00 minimum bid price requirement and attract institutional investors. The decision was approved by stockholders on April 26, 2024, and by the Board on April 30, 2024. No action is required from shareholders as adjustments will be automatic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags

FAQ

What is the current stock price of Glucotrack (GCTK)?

The current stock price of Glucotrack (GCTK) is $5.73 as of September 23, 2025.

What is the market cap of Glucotrack (GCTK)?

The market cap of Glucotrack (GCTK) is approximately 5.5M.
Glucotrack

Nasdaq:GCTK

GCTK Rankings

GCTK Stock Data

5.48M
849.51k
5.55%
0.81%
4.51%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
RUTHERFORD